Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 115 | 2 | 116 | +3 |
| Shares | 75.7M | 107 | 93.4M | +17.7M (+23.4%) |
| Value | $82.5M | $117 | $138.3M | +$55.7M (+67.6%) |
2 institutions that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 6,250,000 | $9.25M | 0.97% |
| DAFNA Capital Management LLC | 1,366,308 | $2.02M | 0.46% |
| Wellington Management Group LLP | 467,545 | $692.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 186,627 | $276.2K | 0.00% |
| Jump Financial, LLC | 72,849 | $107.8K | 0.00% |
| Fifth Third Wealth Advisors LLC | 20,000 | $29.6K | 0.00% |
| Pine Valley Investments Ltd Liability Co | 18,000 | $26.6K | 0.00% |
| HSBC Holdings PLC | 15,218 | $22.5K | 0.00% |
| Qube Research & Technologies Ltd | 13,123 | $19.4K | 0.00% |
| Summit Trail Advisors, LLC | 10,000 | $14.8K | 0.00% |
| Metropolitan Life Insurance Co | 1,666 | $2.47K | 0.00% |
| CWM, LLC | 1,513 | $2.00K | 0.00% |
| Crewe Advisors LLC | 1,016 | $1.50K | 0.00% |
| BFSG, LLC | 355 | $526 | 0.00% |
| Covestor Ltd | 33 | $0 | 0.00% |
Sold out (12)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Laurion Capital Management LP | 433,748 | $472.8K |
| State Board of Administration of Florida Retirement System | 36,970 | $40.3K |
| HRT Financial LP | 35,923 | $39.0K |
| SG Americas Securities, LLC | 30,889 | $34.0K |
| Cetera Advisor Networks LLC | 30,628 | $33.4K |
| XTX Topco Ltd | 27,037 | $29.5K |
| AE Wealth Management LLC | 15,543 | $17.1K |
| Two Sigma Securities, LLC | 12,704 | $13.8K |
| Fisher Asset Management, LLC | 10,000 | $10.9K |
| The PNC Financial Services Group, Inc. | 180 | $196 |
| Northwestern Mutual Wealth Management Co | 20 | $22 |
| Focused Wealth Management, Inc | 8 | $9 |
Not filed for Q1 2024 yet (2)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Coppell Advisory Solutions LLC | 63 | $69 |
| Strategic Investment Solutions, Inc. | 44 | $48 |